Aurentz Vincent is Chief Business Officer at EPIRUS Biopharmaceuticals, Inc. (EPRS). They have made 2 open-market trades across 1 company since 2015, most recently 2015-12-17.
CIK 0001657494
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $18K since 2015, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| EPRS | 2,200 | — |
Shares reported on the most recent Form 4, priced at the 2015-12-21 close. 1 holding could not be priced and is excluded from the total.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.